Studies focusing on aspects of nesfatin-1 and insulin resistance revealed that serum nesfatin-1 levels were decreased in insulin resistance-associated polycystic ovarian syndrome (59) and non-alcoholic fatty liver disease (60). Here, NUCB2 is linked to metabolic dysfunction-associated steatotic liver disease.